Blog

Blog

BY KEVIN HRUSOVSKY, EXECUTIVE CHAIRMAN AND CEO, QUANTERIX

Imagine you’re in a field the size of Alaska. Now, imagine you’re tasked with finding one specific blade of grass in that field. Seems impossible, doesn’t it?

Enter Simoa, our single molecule array technology. Simoa is so sensitive that it allows scientists and researchers to see minute concentrations of biomarkers in blood and other bodily fluids at this equivalence.

By Kevin Hrusovsky, Executive Chairman and CEO, Quanterix

Alzheimer’s disease is a dangerous and ultimately fatal form of dementia, and according to recent data from the Centers for Disease Control (CDC), Alzheimer’s is the sixth leading cause of death in the United States, accounting for 3.6% of all deaths. What’s more, the CDC also reports that the number of deaths from Alzheimer’s disease in the United States has risen by 55% in the last 15 years alone. With the numbers on the rise, it’s more important than ever that we continue to accelerate research to advance treatment options for this and other progressive neurodegenerative diseases.

We had the privilege of hosting a webinar led by Dr. Jennifer E. Van Eyk, professor of medicine at Cedars-Sinai Medical Center. Jennifer has been a long-time friend and supporter of Quanterix and we were honored to have her share her expertise with attendees. During the webinar, Dr. Van Eyk discussed the need for precise protein quantification and identification to advance personalized medicine, which is a topic that is very near and dear to the work we do here at Quanterix. The future of healthcare relies on our ability to accelerate precision medicine to diagnose diseases before symptoms present. 

By Kevin Hrusovsky, Executive Chairman and CEO, Quanterix
It takes an average of 17 years to bring a scientific discovery into clinical practice. This statistic, which has been validated by research published in Public Health Reports and the Journal of the Royal Society of Medicine, reveals a troubling reality for many patients in desperate need of the new practices, tests, drugs and technologies stuck in the years-long gap between research and implementation into healthcare practices and policies. 
By Dr. Andreas Jeromin, Ph.D., Chief Medical Officer (Consulting), Quanterix

When we think of the letters N-F-L, our minds are drawn to football and the National Football League. However, NfL, or ineurofilament light chain as the non-abbreviated name, is also a powerful protein that has shown promise for the early detection and diagnosis of brain injuries, as well as several neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease.

This website uses cookies. By continuing to use this website you are acknowledging and agree with our cookie policy.

AgreeLearn more